@article{17392f83522f49fb9b000b6988c43ac5,
title = "Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC",
abstract = "Introduction: Checkpoint inhibitor pneumonitis (CIP) is a serious toxicity of anti–programmed death-(ligand) 1 immunotherapy. Whether pretreatment differences in pulmonary function exist in patients who develop CIP is unknown. We analyzed the pulmonary function tests (PFTs) of patients with NSCLC treated with immune checkpoint inhibitors (ICIs) to evaluate whether pretreatment lung function was associated with CIP development. Methods: Patients were included if they completed greater than or equal to 1 PFT within 2 years preceding ICI initiation. CIP status (CIP+: developed CIP, CIP−: did not develop CIP) was determined clinically. Generalized estimating equation–based linear regression was used to evaluate the effects of time and CIP on lung function. Primary outcomes included the following: percent-predicted forced expiratory volume in 1 second (FEV1pp), percent-predicted forced vital capacity (FVCpp), and FEV1/FVC. Results: A total of 43 patients (34 CIP−, 9 CIP+) with 79 PFTs (59 CIP−, 20 CIP+) were included. CIP+ patients had a 21.7% lower pretreatment FEV1pp compared with the CIP− group (95% confidence interval: −38.6 to −4.7). No statistically significant differences in FVCpp or FEV1/FVC were observed. The prevalence of obstructive lung disease was similar in both groups at 67% and 62% for the CIP+ and CIP− cohorts, as was the prevalence of current/former smoking at 100% and 93%, respectively. Conclusions: Pretherapy differences in lung function were evident between patients who did and did not develop CIP, though the prevalence of obstructive lung disease was similar. Prospective studies are needed to validate these findings, inform potential risk factors for CIP, and investigate the effects of ICI treatment and CIP on pulmonary function in patients with NSCLC.",
keywords = "Immune checkpoint inhibitor, Immunotherapy, Non–small cell lung cancer, Pneumonitis, Pulmonary function tests",
author = "Reuss, {Joshua E.} and Emily Brigham and Psoter, {Kevin J.} and Voong, {Khinh Ranh} and Bairavi Shankar and Ettinger, {David S.} and Marrone, {Kristen A.} and Hann, {Christine L.} and Benjamin Levy and Feliciano, {Josephine L.} and Brahmer, {Julie R.} and David Feller-Kopman and Lerner, {Andrew D.} and Hans Lee and Lonny Yarmus and Hales, {Russell K.} and Franco D'Alessio and Danoff, {Sonye K.} and Forde, {Patrick M.} and Karthik Suresh and Jarushka Naidoo",
note = "Funding Information: Disclosure: Dr. Reuss reports receiving grants from Conquer Cancer: The American Society of Clinical Oncology Foundation, outside of the submitted work. Dr. Brigham reports receiving grants from the National Institutes of Health, during the conduct of the study. Dr. Voong reports receiving grants from Lung Cancer Research Foundation, outside of the submitted work. Dr. Ettinger reports serving on the advisory boards of BeyondSpring Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly & Co., and Guardant Health, Inc., outside of the submitted work. Dr. Hann reports receiving grants from AbbVie, AstraZeneca, Bristol-Myers Squibb, and Genentech/Roche, outside of the submitted work; and serving on the advisory boards of AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, and Ascentage, outside of the submitted work. Dr. Levy reports receiving grants from Eli Lilly, Genentech, Bristol-Myers Squibb, AstraZeneca, Turning Point Therapeutics, and Amgen, outside of the submitted work; and serving on the advisory boards of Eli Lilly, Genentech, AstraZeneca, Celgene, Pfizer, Merck, Novartis, and Takeda, outside of the submitted work. Dr. Feliciano reports receiving grants from AstraZeneca, outside of the submitted work; and serving on the advisory boards of AstraZeneca, Bristol-Myers Squibb, Merck, Genentech, Takeda, and Eli Lilly, outside of the submitted work. Dr. Brahmer reports receiving grants from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics, Inc., and Revolution Medicines, outside of the submitted work; serving on the advisory boards of Amgen, Bristol-Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, and Sanofi, outside of the submitted work; serving on the Data and Safety Monitory boards of GlaxoSmithKline and Sanofi, outside of the submitted work; and receiving personal fees from Genentech/Roche, outside of the submitted work. Dr. Forde reports receiving grants from AstraZeneca, Bristol-Myers Squibb, Kyowa, Novartis, and Corvus, outside of the submitted work; and serving on the advisory boards of AbbVie, AstraZeneca, and Bristol-Myers Squibb, outside of the submitted work. Dr. Suresh reports receiving grants from the National Institutes of Health, during the conduct of the study. Dr. Naidoo reports receiving grants from AstraZeneca and Merck, outside of the submitted work; serving on the advisory boards of AstraZeneca, Bristol-Myers Squibb, and Genentech/Roche, outside of the submitted work; and receiving personal fees from AstraZeneca, Bristol-Myers Squibb, and Merck, outside of the submitted work. The remaining authors declare no conflict of interest. Funding Information: Disclosure: Dr. Reuss reports receiving grants from Conquer Cancer: The American Society of Clinical Oncology Foundation, outside of the submitted work. Dr. Brigham reports receiving grants from the National Institutes of Health, during the conduct of the study. Dr. Voong reports receiving grants from Lung Cancer Research Foundation, outside of the submitted work. Dr. Ettinger reports serving on the advisory boards of BeyondSpring Pharmaceuticals, Bristol-Myers Squibb , Eli Lilly & Co., and Guardant Health, Inc., outside of the submitted work. Dr. Hann reports receiving grants from AbbVie , AstraZeneca , Bristol-Myers Squibb , and Genentech / Roche , outside of the submitted work; and serving on the advisory boards of AbbVie , AstraZeneca , Bristol-Myers Squibb , Genentech / Roche , and Ascentage, outside of the submitted work. Dr. Levy reports receiving grants from Eli Lilly , Genentech , Bristol-Myers Squibb , AstraZeneca , Turning Point Therapeutics, and Amgen, outside of the submitted work; and serving on the advisory boards of Eli Lilly , Genentech , AstraZeneca , Celgene, Pfizer , Merck , Novartis , and Takeda, outside of the submitted work. Dr. Feliciano reports receiving grants from AstraZeneca, outside of the submitted work; and serving on the advisory boards of AstraZeneca , Bristol-Myers Squibb , Merck , Genentech , Takeda, and Eli Lilly, outside of the submitted work. Dr. Brahmer reports receiving grants from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics, Inc., and Revolution Medicines, outside of the submitted work; serving on the advisory boards of Amgen, Bristol-Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, and Sanofi, outside of the submitted work; serving on the Data and Safety Monitory boards of GlaxoSmithKline and Sanofi, outside of the submitted work; and receiving personal fees from Genentech/Roche, outside of the submitted work. Dr. Forde reports receiving grants from AstraZeneca , Bristol-Myers Squibb , Kyowa, Novartis , and Corvus, outside of the submitted work; and serving on the advisory boards of AbbVie, AstraZeneca, and Bristol-Myers Squibb, outside of the submitted work. Dr. Suresh reports receiving grants from the National Institutes of Health, during the conduct of the study. Dr. Naidoo reports receiving grants from AstraZeneca and Merck, outside of the submitted work; serving on the advisory boards of AstraZeneca, Bristol-Myers Squibb, and Genentech/Roche, outside of the submitted work; and receiving personal fees from AstraZeneca, Bristol-Myers Squibb, and Merck, outside of the submitted work. The remaining authors declare no conflict of interest. Funding Information: Financial support for this study was provided by the National Institutes of Health (EB—1K23ES029105-01A1; KS—K08L132055). The funding source played no role in the study design, manuscript writing, or decision to submit the manuscript. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
month = oct,
doi = "10.1016/j.jtocrr.2021.100220",
language = "English (US)",
volume = "2",
journal = "JTO Clinical and Research Reports",
issn = "2666-3643",
publisher = "Elsevier Inc.",
number = "10",
}